Posts tagged ‘heart’

December 26, 2013

Healthcare investing: artificial heart implant maker may seek new funding

PARIS (Reuters) – France’s Carmat, developer of an artificial heart implanted into its first patient last week, may seek an injection of funds from fresh investors to help tap a potential multi-billion-euro global market, a senior executive said.

“We could, at some point, call on new investors,” Carmat co-founder Philippe Pouletty was quoted saying by Le Monde newspaper on Saturday. “Our aim, if possible, is to remain independent.”

The company said after Friday’s stock market close it had carried out its first implant of an artificial heart that can beat for up to five years, marking a potential breakthrough for patients with heart conditions.

Company officials warned it was too early to draw firm conclusions from the operation carried out in a Paris hospital on Wednesday, but noted the male patient in his 70s was conscious and talking in intensive care.

Pouletty told Le Monde that, once put on sale, the 130,000 euro ($177,700) device had a potential market of 100,000 patients in the United States and Europe.

“The medical need is significant, with a market potential of several billion euros,” Pouletty said. “The issue is whether it will be reimbursed by healthcare systems. We are confident about that (as) much less sophisticated artificial hearts of comparable cost are already authorized and reimbursed in a number of countries.”

Shares in the company closed at 102.86 euros on Friday, to give it a stock market value of about 436 million euros. The stock was listed on the Paris bourse in 2010 at 18 euros.

Pouletty, director of investment fund Truffle Capital which funded Carmat’s launch, said the group had raised 16 million euros with its initial stock market flotation and a further 30 million via a share issue in 2011. It also won 33 million funding from France’s Public Investment Bank (BPI).

See on

See on – Pharmaceutical Industry digital vision

November 17, 2013

French company aims for artificial heart approval by early 2015

The French company is also seeking a partner in the United States to enter the world’s largest healthcare market.

PARIS (Reuters) – Carmat hopes to finish human trials of its artificial heart by the end of next year and to obtain regulatory approval for an EU launch by early 2015, its chief executive told Reuters.

The French company is also seeking a partner in the United States to enter the world’s largest healthcare market, and is in contact with Johnson & Johnson, Medtronic, St Jude Medical and Edwards Lifesciences, Marcello Conviti said.

Heart assistance devices have been in use for decades as a temporary solution for patients awaiting a transplant but Carmat’s product is designed to replace the heart for up to five years, mimicking nature’s work using biological materials and sensors. It targets the thousands of patients who die each year while waiting for a donor.

Carmat estimates around 100,000 patients in the United States and Europe could benefit from its artificial heart, which would make the market worth more than 16 billion euros ($21.5 billion).

In September, Carmat got the green light from French authorities to test the first human implants of the device on four patients in three French hospitals.

Earlier this year, it won approval to proceed with human implants in Belgium, Poland, Slovenia and Saudi Arabia.

“For now the tests are going as planned,” Conviti said in an interview on Thursday.

He would not give details but said patients selected suffered from terminal heart failure and had only a few days or weeks to live.

See on

From Pharmaceutical Industry digital vision

Tags: ,
October 14, 2013

IBM to help doctors fight heart disease with smarter use of data

How do you know if you’re at risk for heart failure?

The answers might be right there in a doctor’s records, said Shahram Ebadollahi, a director in the healthcare informatics group at IBM Research told CITEworld. They just need to dig through all their data and connect the dots.

IBM Research, Sutter Health, and Geisinger Health System have been granted $2 million for a joint research from the National Institutes of Health (NIH) to develop a new type of analytics and application methods that could help doctors detect heart failure years earlier than they do now.

IBM and its health care partners hope to develop methods that will catch signs of heart failure anywhere from six to 24 months ahead of time. With enough time, the patient might be able to fix it with lifestyle changes, or get on the proper medications.

The project is dependent on doctors using electronic health records. If they still do everything on paper, it won’t do any good, said Ebadollahi. The system will examine health records to help detect heart failure earlier, identify best practices that help health systems nationwide integrate analytics into primary care, and take an expansive view of a patient’s health history.

See on

From Pharmaceutical Industry digital vision

Tags: ,